- Home
- TW vs RPRX Comparison
TW vs RPRX Comparison
Compare TW & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TW | RPRX |
|---|---|---|
| Founded | 1996 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.9B | 22.0B |
| IPO Year | 2019 | 2020 |
Fundamental Metrics
Financial Performance| Metric | TW | RPRX |
|---|---|---|
| Price | $97.82 | $54.13 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 5 |
| Target Price | ★ $135.25 | $51.40 |
| AVG Volume (30 Days) | 1.5M | ★ 3.1M |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | 0.47% | ★ 1.90% |
| EPS Growth | ★ 62.23 | N/A |
| EPS | ★ 0.96 | 0.67 |
| Revenue | $892,659,000.00 | ★ $2,378,193,000.00 |
| Revenue This Year | $18.07 | $38.63 |
| Revenue Next Year | $10.66 | $4.73 |
| P/E Ratio | $104.36 | ★ $82.36 |
| Revenue Growth | ★ 15.10 | 5.06 |
| 52 Week Low | $97.06 | $33.30 |
| 52 Week High | $147.49 | $55.86 |
Technical Indicators
Market Signals| Indicator | TW | RPRX |
|---|---|---|
| Relative Strength Index (RSI) | 25.45 | 61.47 |
| Support Level | $97.06 | $35.35 |
| Resistance Level | $111.11 | N/A |
| Average True Range (ATR) | 3.31 | 1.13 |
| MACD | -0.74 | 0.05 |
| Stochastic Oscillator | 19.93 | 60.28 |
Price Performance
Historical ComparisonAbout TW Tradeweb Markets Inc.
Founded in 1998 and headquartered in New York City, Tradeweb Markets is a leading fixed-income trading platform. While it does offer electronic processing for some voice-negotiated trades, the company focuses primarily on providing electronic trading networks that connect broker/dealers, institutional clients, and retail customers. While the company offers trading in a wide variety of products, the bulk of its business is in US and European government debt, mortgage-backed securities, interest-rate swaps, and US and international corporate bonds. The firm also sells fixed-income trading and price data, primarily through a deal with Refinitiv's Eikon service.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.